Trials / Completed
CompletedNCT02537054
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)
Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- University Hospital, Bonn · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Aflibercept (Eylea) is effective in the treatment of choroidal neovascularization and fibrovascular proliferation in patients with pseudoxanthoma elasticum (PXE) in terms of preservation or improvement of visual acuity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept | Intravitreal injection |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2018-07-02
- Completion
- 2018-07-02
- First posted
- 2015-09-01
- Last updated
- 2019-05-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02537054. Inclusion in this directory is not an endorsement.